AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Aeglea BioTherapeutics, Inc., (the “Company”) today announced the appointment of Anthony Quinn, M.B Ch.B, Ph.D., FRCP as interim chief medical officer, effective immediately. Dr. Quinn also serves on the Company’s Board of Directors and, most recently, was executive vice president, chief medical officer and head of research & development at Synageva BioPharma Corp. until its acquisition by Alexion Pharmaceuticals in 2015. Dr. Quinn will oversee the medical strategy and clinical development of AEB1102, the Company’s lead product candidate, for the treatment of Arginase I deficiency as well as the Company’s additional rare genetic diseases and oncology programs.

“Anthony has been a key member of our board and his extensive experience in rare disease drug development has already benefited our clinical development programs,” said David G. Lowe, Ph.D., chief executive officer of Aeglea. “Anthony’s leadership will be critical during this time of growth and I look forward to partnering with him in this role while we continue our search for a full-time chief medical officer.”

“I look forward to working with David and his leadership team at Aeglea to advance the clinical development of our lead program AEB1102 in rare genetic diseases and cancer as well as to continue building the clinical development organization,” said Dr. Quinn.

F. Andrew Dorr, M.D., the Company’s previous interim chief medical officer, will transition his work to focus on the clinical development of the Company’s oncology programs.

The information furnished with this report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

About AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE)

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company’s product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.

AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE) Recent Trading Information

AEGLEA BIOTHERAPEUTICS, INC. (NASDAQ:AGLE) closed its last trading session down -0.12 at 6.90 with 16,983 shares trading hands.